HOME >> BIOLOGY >> NEWS
Biosite reports on presentation of preliminary data from sepsis program

SAN DIEGO and BRUSSELS, Belgium Biosite Incorporated (Nasdaq:BSTE) today announced preliminary results of a sample collection study aimed at identifying a biomarker panel that could potentially aid in the assessment for risk of sepsis progression. Sepsis is an often fatal condition with limited therapeutic options. Clinical investigator, Emanuel P. Rivers, M.D., MPH, vice chairman and director of research at the department of emergency medicine at Henry Ford Hospital in Detroit, presented the data at the 27th International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels.

In this study, we identified a combination of three biomarkers that performed better when compared to several other individual biomarkers, said Dr. Rivers. This preliminary study suggests that these biomarkers may be a clinically useful tool in the assessment of risk of sepsis progression within 72 hours of patients presenting to the emergency department and meeting the diagnostic criteria for sepsis. We look forward to future studies that will be aimed at substantiating these findings.

We are encouraged by this study and will advance this sepsis biomarker panel to the next step in our clinical process, said Ken Buechler, Ph.D., Biosite president and chief scientific officer. We are on track to launch a prospective multi-center clinical study in the second quarter of 2007 to validate the clinical utility of this panel and compile data needed for an FDA submission.

The biomarkers on the panel, neutrophil gelatinase-associated lipocalin (NGAL), c-reactive protein (CRP), and macrophage inflammatory protein-3 (MIP-3), were selected from 150 biomarkers studied through the Biosite Discovery program. The panel incorporates Biosites proprietary MultiMarker Index (MMX) Value feature that uses an algorithm to generate a single quantitative result from multiple simultaneous biomarker measurements. Biosite intends to commercialize the panel of biomarkers
'"/>

Contact: Nicole Beckstrand
nbeckstrand@biosite.com
858-805-2803
Biosite Incorporated
28-Mar-2007


Page: 1 2

Related biology news :

1. ChemGenex reports successful personalized dosing of Quinamed at ASCO
2. 1 month post launch, Interactive Autism Network reports 13,000 participants
3. Biolex reports potential for more potent, efficacious antibodies in Nature Biotechnology
4. Orexigen reports positive phase II results for Excalia Combination-Therapy to treat obesity
5. Dinosaurs climate shifted too, reports show
6. The New England Journal of Medicine reports data on eculizumab for the treatment of PNH
7. Portion distortion may contribute to expanding waistlines, study reports
8. Study reports findings on lung cancer death rates in never smokers
9. Breast implants not associated with cancer risk, study reports
10. Paper reports discovery of virus implicated in genetics of prostate cancer
11. First analysis of FDAs mifepristone adverse event reports

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
(Date:2/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... present at the LEERINK Partners 6th Annual Global Healthcare ... Wednesday, February 15, 2017 at 10 a.m. Eastern Time. ... can be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... SAN FRANCISCO , Feb. 23, 2017 ... company, and Beyond Type 1, a not-for-profit advocacy and ... today announced a grant from Beyond Type 1 to ... type 1 and other insulin-requiring diabetes.  ... innovative stem cell-derived cell replacement therapies with a focus ...
(Date:2/22/2017)... 2017  PrimeVax Immuno-Oncology, Inc. announced today its CEO, ... Annual Biocom Global Life Science Partnering Conference.  The presentation ... at the Torrey Pines Lodge, in San Diego.  ... Biocom who have chosen our company, amongst numerous others, ... investors, and clinical researchers," said Mr. Chen. "In contrast ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the leading ... around the world, is pleased to announce the launch of a new scholarship for ... (STEM) fields. , This merit-based scholarship is open to all high school seniors, 17 ...
(Date:2/22/2017)... ... 22, 2017 , ... Pharma and biotech consulting firm ... Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins brings 14 years ... than a decade with leading market research firm, GfK. He began his pharma ...
Breaking Biology Technology:
Cached News: